291 related articles for article (PubMed ID: 24666649)
21. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
23. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
[TBL] [Abstract][Full Text] [Related]
24. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
[TBL] [Abstract][Full Text] [Related]
25. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
Pinner NA; Hurdle AC; Oliphant C; Reaves A; Lobo B; Sills A
World Neurosurg; 2010 Dec; 74(6):631-5. PubMed ID: 21492631
[TBL] [Abstract][Full Text] [Related]
26. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
28. Discussion of "Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa".
Van Dusen R
Am J Surg; 2018 May; 215(5):780-781. PubMed ID: 29366484
[TBL] [Abstract][Full Text] [Related]
29. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
Dickneite G; Dörr B; Kaspereit F; Tanaka KA
J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
[TBL] [Abstract][Full Text] [Related]
30. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
[TBL] [Abstract][Full Text] [Related]
31. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
32. Reversal of dabigatran effects in models of thrombin generation and hemostasis by factor VIIa and prothrombin complex concentrate.
Hoffman M; Volovyk Z; Monroe DM
Anesthesiology; 2015 Feb; 122(2):353-62. PubMed ID: 25502064
[TBL] [Abstract][Full Text] [Related]
33. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.
Knight C; Danø AM; Kennedy-Martin T
Adv Ther; 2009 Jan; 26(1):68-88. PubMed ID: 19156372
[TBL] [Abstract][Full Text] [Related]
34. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
Dickneite G; Hoffman M
Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
[TBL] [Abstract][Full Text] [Related]
35. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
Taketomi T; Szlam F; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):106-8. PubMed ID: 18180627
[No Abstract] [Full Text] [Related]
36. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
[TBL] [Abstract][Full Text] [Related]
37. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
38. Current state of knowledge on oral anticoagulant reversal using procoagulant factors.
Nitzki-George D; Wozniak I; Caprini JA
Ann Pharmacother; 2013 Jun; 47(6):841-55. PubMed ID: 23695644
[TBL] [Abstract][Full Text] [Related]
39. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
40. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit.
Le Saché F; Le Bonniec B; Gaussem P; Dizier B; Tagzirt M; Godier A; Emmerich J; Samama CM
Br J Anaesth; 2012 Apr; 108(4):586-93. PubMed ID: 22258204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]